Axsome Therapeutics AXSM Income Statement
| Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | ||
|---|---|---|---|---|---|---|
| $191.2M+57.4% | $196M+65.0% | $170.99M+63.2% | $150.04M+72.1% | $121.46M+62.0% | ||
| $14.73M+50.4% | $12.33M+17.3% | $11.91M+41.2% | $13.45M+67.0% | $9.79M+55.5% | ||
| $176.48M+58.0% | $183.67M+69.7% | $159.08M+65.1% | $136.59M+72.7% | $111.67M+62.5% | ||
| 92.3%+0.4pp | 93.7%+2.6pp | 93%+1.1pp | 91%+0.3pp | 91.9%+0.3pp | ||
| $52.68M+17.6% | $48.79M-11.3% | $40.16M-11.5% | $49.54M-0.6% | $44.79M+21.6% | ||
| $185M+53.2% | $169.3M+49.5% | $150.24M+57.2% | $130.28M+25.8% | $120.79M+22.0% | ||
| $254.56M+42.7% | $222.96M+16.5% | $217.1M+29.7% | $186.76M+13.0% | $178.45M+25.4% | ||
| -$63.36M-11.2% | -$26.96M+62.9% | -$46.11M+26.4% | -$36.71M+53.0% | -$56.98M+15.3% | ||
| -33.1%+13.8pp | -13.8%+47.4pp | -27%+32.8pp | -24.5%+65.1pp | -46.9%+42.8pp | ||
| -$64.54M-8.6% | -$28.13M+62.4% | -$47.23M+26.9% | -$48.93M+38.3% | -$59.41M+13.1% | ||
| $0— | —— | $0— | -$960K— | $0— | ||
| -$64.54M-8.6% | -$28.56M+61.9% | -$47.23M+26.9% | -$47.97M+39.5% | -$59.41M+13.1% | ||
| -33.8%+15.2pp | -14.6%+48.5pp | -27.6%+34.0pp | -32%+59.1pp | -48.9%+42.2pp | ||
| -$1.26-3.3% | -$0.55+64.3% | -$0.94+29.9% | -$0.97+41.9% | -$1.22+15.3% | ||
| -$61.67M-11.6% | -$25.24M+64.4% | -$44.38M+27.1% | -$35.01M+54.1% | -$55.26M+15.7% | ||
| -32.3%+13.2pp | -12.9%+46.8pp | -26%+32.2pp | -23.3%+64.2pp | -45.5%+41.9pp | ||
| -$63.36M-11.2% | -$26.96M+62.9% | -$46.11M+26.4% | -$36.71M+53.0% | -$56.98M+15.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Axsome Therapeutics's revenue?
- Axsome Therapeutics (AXSM) generated $708.2M in revenue over the trailing twelve months, up 63.9% year over year.
- Is Axsome Therapeutics profitable?
- Axsome Therapeutics is not currently profitable: it reported a net loss of $188.3M over the trailing twelve months, a -26.6% net margin.
- What are Axsome Therapeutics's profit margins?
- Gross margin is 92.6% and operating margin is -24.4%, with a -26.6% net margin.
- What is Axsome Therapeutics's earnings per share?
- Axsome Therapeutics's diluted EPS over the trailing twelve months is $-3.72.
- Where does Axsome Therapeutics's income statement data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
